Non-adherence to the RT protocol was associated with an inferior OS and loco-regional control. These results underline the importance of RTQA.

Identification of suspicious PSMA-PET/CT-positive lymph node (LN) metastases (LNM) from prostate cancer (PCa) during lymphadenectomy (LA) is challenging. We evaluated an 111In-labelled PSMA ligand (DKFZ-617, referred to as [111In]PSMA-617) as a γ-emitting tracer for intraoperative γ-probe application for resected tissue samples in PCa patients. Forty-eight hours prior to LA, [111In]PSMA-617 was administered intravenously in 23 patients with suspected LNM on PSMA-PET/CT (n = 21 with biochemical relapse, n = 2 at primary therapy). Resected tissue samples (LN, LNM and fibrofatty tissue) were measured ex situ by a γ-probe expressed as counts per second (CPSnorm). [111In]PSMA-617 tissue sample uptake was measured by a germanium detector for verification and calculated as %IAlbm (percent injected activity per kilogram lean body mass at time of surgery). Based on a clinical requirement for a specificity > 95%, thresholds for both ex situ measurements were chosen accordingly. Correlation of the results from PET/CT, γ-probe and germanium detector with histopathology was done. Eight hundred sixty-four LNs (197 LNM) were removed from 275 subregions in 23 patients, on average 8.6 ± 14.9 LNM per patient. One hundred four of 275 tissue samples showed cancer. Median γ-probe and germanium detector results were significantly different between tumour-affected (33.5 CPSnorm, 0.71 %IAlbm) and tumour-free subregions (3.0 CPSnorm, 0.03 %IAlbm) (each p value < 0.0001). For the chosen γ-probe cut-off (CPSnorm > 23) and germanium detector cut-off (%IAlbm > 0.27), 64 and 74 true-positive and 158 true-negative samples for both measurements were identified. Thirty-nine and 30 false-negative and 6 and 5 false-positive tissue samples were identified by γ-probe and germanium detector measurements. [111In]PSMA-617 application for LA is feasible in terms of an intraoperative real-time measurement with a γ-probe for detection of tumour-affected tissue samples. γ-probe results can be confirmed by precise germanium detector measurements and were significantly different between tumour-affected and tumour-free samples.

BACKGROUND:With increasingly precise radiotherapy and advanced medical imaging, the concept of radiotherapy target volume planning might be redefined with the aim of improving outcomes. We aimed to investigate whether target volume reduction is feasible and effective compared with conventional planning in the context of radical chemoradiotherapy for patients with locally advanced non-small-cell lung cancer. METHODS:We did a multicentre, open-label, randomised, controlled trial (PET-Plan; ARO-2009-09) in 24 centres in Austria, Germany, and Switzerland. Previously untreated patients (aged older than 18 years) with inoperable locally advanced non-small-cell lung cancer suitable for chemoradiotherapy and an Eastern Cooperative Oncology Group performance status of less than 3 were included. Undergoing 18F-fluorodeoxyglucose (18F-FDG) PET and CT for treatment planning, patients were randomly assigned (1:1) using a random number generator and block sizes between four and six to target volume delineation informed by 18F-FDG PET and CT plus elective nodal irradiation (conventional target group) or target volumes informed by PET alone (18F-FDG PET-based target group). Randomisation was stratified by centre and Union for International Cancer Control stage. In both groups, dose-escalated radiotherapy (60-74 Gy, 2 Gy per fraction) was planned to the respective target volumes and applied with concurrent platinum-based chemotherapy. The primary endpoint was time to locoregional progression from randomisation with the objective to test non-inferiority of 18F-FDG PET-based planning with a prespecified hazard ratio (HR) margin of 1·25. The per-protocol set was included in the primary analysis. The safety set included all patients receiving any study-specific treatment. Patients and study staff were not masked to treatment assignment. This study is registered with ClinicalTrials.gov, NCT00697333. FINDINGS:From May 13, 2009, to Dec 5, 2016, 205 of 311 recruited patients were randomly assigned to the conventional target group (n=99) or the 18F-FDG PET-based target group (n=106; the intention-to-treat set), and 172 patients were treated per protocol (84 patients in the conventional target group and 88 in the 18F-FDG PET-based target group). At a median follow-up of 29 months (IQR 9-54), the risk of locoregional progression in the 18F-FDG PET-based target group was non-inferior to, and in fact lower than, that in the conventional target group in the per-protocol set (14% [95% CI 5-21] vs 29% [17-38] at 1 year; HR 0·57 [95% CI 0·30-1·06]). The risk of locoregional progression in the 18F-FDG PET-based target group was also non-inferior to that in the conventional target group in the intention-to-treat set (17% [95% CI 9-24] vs 30% [20-39] at 1 year; HR 0·64 [95% CI 0·37-1·10]). The most common acute grade 3 or worse toxicity was oesophagitis or dysphagia (16 [16%] of 99 patients in the conventional target group vs 17 [16%] of 105 patients in the 18F-FDG PET-based target group); the most common late toxicities were lung-related (12 [12%] vs 11 [10%]). 20 deaths potentially related to study treatment were reported (seven vs 13). INTERPRETATION:18F-FDG PET-based planning could potentially improve local control and does not seem to increase toxicity in patients with chemoradiotherapy-treated locally advanced non-small-cell lung cancer. Imaging-based target volume reduction in this setting is, therefore, feasible, and could potentially be considered standard of care. The procedures established might also support imaging-based target volume reduction concepts for other tumours. FUNDING:German Cancer Aid (Deutsche Krebshilfe).

Accurate detection of prostate cancer lymph node metastases (LNM) through PET/CT before lymphadenectomy is crucial for successful therapy. PET/CT with choline derivatives used to be the standard tool for imaging metastases, whereas 68Ga-PSMA (prostate-specific membrane antigen) PET/CT was introduced recently. Both PET techniques were investigated with respect to what extent the detection rate of LNM depends on the size of tumor deposits (TDs) within LNM. Methods: Documenting the switch from the use of 18F-choline to 68Ga-PSMA in 2014, we used 2 patient cohorts undergoing a template lymphadenectomy because of a PET/CT indicating LNM. Forty-four and 40 patients underwent PET/CT with 18F-choline or 68Ga-PSMA ligand, respectively. In total, 226 LNM (125 18F-choline, 101 68Ga-PSMA) originated from 73 salvage lymphadenectomies at biochemical recurrence and from 11 primary lymphadenectomies at radical prostatectomy. LNM eligible for direct correlation of PET/CT to histopathology were identified from lymphadenectomies conducted in small anatomic subregions, with 1 LNM (condition 1) or 1–2 LNM (condition 2). Longitudinal and short diameters of TD within LNM were determined by histopathology, allowing linking of the size of TD in LNM to the detection threshold of PET/CT. Diameters associated with a detection rate of 50% and 90% (d50%, d90%) were calculated on the basis of logistic growth curve models fitted. Results: Gleason score, number of removed LNs, and subregions for lymphadenectomy per patient did not differ significantly between the 18F-choline and 68Ga-PSMA groups. The median prostate-specific antigen level at imaging and number of LNM per patient were significantly higher in the 18F-choline group (3.4 ng/mL, n = 34) than in the 68Ga-PSMA group (2.2 ng/mL, n = 28; both P < 0.05). Longitudinal and short diameters of TD in LNM to reach d90% were 11.2 and 7.4 mm, respectively, for 18F-choline PET/CT and 6.3 and 4.9 mm, respectively, for 68Ga-PSMA PET/CT. Corresponding diameters to reach d50% were 5.5 and 3.3 mm, respectively, for 18F-choline PET/CT and 3.7 and 2.3 mm, respectively, for 68Ga-PSMA PET/CT. Detection rates were significantly higher under 68Ga-PSMA (P = 0.005 and 0.04 for longitudinal and short diameter). Conclusion: 68Ga-PSMA PET/CT is superior to 18F-choline PET/CT in the detection of LNM. Whether those results will lead to an improved patient outcome after 68Ga-PSMA PET–guided therapy needs to be investigated by further studies.

ESTRO 3812.5 / 3.1%, respectively (p=0.94).There was no statistical difference between 2 cohorts for each toxicity. ConclusionModerate hypofractionated proton beam therapy for prostate cancer is feasible.Further follow-up is needed to evaluate late toxicity.

S78 ESTRO 38information is used in DRE based nomograms.Furthermore, by incorporating additional core-specific biopsy information instead of the percentage of positive cores as mentioned in the existing nomograms, this nomogram could handle with the paradigm shift from saturation biopsies towards targeted biopsies.This updated nomogram could be a useful tool that helps urologists and radiation oncologists to accurately predict the likelihood of LNI before treatment.

To prospectively assess in HNSCC patients the effect of chemoradiotherapy (CRT) on tumor hypoxia and tissue properties with [18F]FMISO PET/CT (FMISO PET) and multiparametric (mp) MRI at baseline and at an early (week 2) and late (week 5) time point during treatment and to analyze whether mpMRI and PET parameters are related with outcome. Patients with stage III to IVb HNSCC undergoing definitive CRT (total dose 70 Gy, 3 cycles of cisplatin over 7 weeks) were included. Patients were prospectively imaged with [18F]FDG PET/CT at baseline and with serial FMISO PET and serial 3 Tesla mpMRI for T1w-, T2w- as well as contrast-enhanced perfusion and diffusion-weighted measurements (ktrans, ve and apparent diffusion coefficient (ADC) maps) in weeks 0, 2 and 5. Patients were identified as responders or non-responders during follow-up regarding loco-regional control (LRC) and overall survival (OS). Tumor volumes were contoured and SUVmax FMISO PET and mean values for mpMRI parameters were compared between responders and non-responders with the t-test and Log Rank test at a significance level of p≤0.05. A complete set of serial FMISO PET data and 3 T MRI was available in 21 patients. Of those, 12 patients were diagnosed with local recurrence. Baseline tumor volume and FMISO-PET-derived tumor hypoxia (SUVmax FMISO) were higher among patients with local recurrence as compared to locally controlled patients (p=n.s.). On Kaplan-Meier analysis stratified at median change in SUVmax FMISO between weeks 0 to 5 (ΔFMISOwk0-5), LRC was higher for ΔFMISOwk0-5 > median (p=n.s.). For ADC, an increase was found from week 0 to 5 (responders > non-responders). LRC was significantly higher for patients with ΔADCwk0-5 and %ΔADCwk0-5 > median (Log Rank, p=0.04 and p=0.005). In perfusion MRI, ktrans increased from week 0 to 5 for both non-responders and responders (p=n.s.). For non-responders, ktrans reached a maximum at week 2, while for responders, ktrans showed a steady increase until week 5. Interstitial space volume fraction ve did not differ significantly between responders and non-responders and increased between week 0 and 5 (p=n.s.). Baseline ADC below median was significantly (p=0.013) correlated with improved OS. ADCweek2 below median was associated with improved OS (p=n.s.). Baseline ve below median was significantly correlated with improved OS (p=0.043) and associated with increased LRC (p=n.s.). Multiparametric MRI parameters ADC and interstitial space volume fraction ve obtained at baseline were significantly correlated with improved OS and an increase of ADC between week 0 to 5 was significantly correlated with improved LRC. FMISO-PET-derived tumor hypoxia and mean values of MRI parameters ktrans and ve differed between relapsing and non-relapsing patients, however without reaching statistical significance in this cohort. The correlations found for ve and ADC may suggest predictive power for OS and LRC depending on baseline imaging and the dynamics of ADC.

Detection of local progression (LP) after stereotactic body radiotherapy (SBRT) for lung lesions can be difficult because of radiation-induced lung changes in CT scans. High–risk CT-features (HRF-CT) for prediction of LP have been proposed, the role of 18F-FDG-PET remains unclear. Here previously defined HRF-CT and 18F-FDG-PET-imaging features (HRF-PET) were evaluated in a prospective SBRT-trial cohort (STRIPE) under "real-life conditions". Four independent and blinded observers scored follow-up (FU)-CT and 18F-FDG-PET/CT images of 65 pulmonary lesions after SBRT with a structured questionnaire assessing RECIST and HRF-CT ((sequential) enlarging opacity, bulging margin, linear margin disappearance, loss of air bronchogram, craniocaudal growth). If LP was suspected, the respective 18F-FDG-PET images were analyzed qualitatively, then quantitatively. Additional interview independent qualitative evaluation of all 107 FU-PET scans was performed. Inter-observer Agreement (IOA) was determined using Cohen's kappa. Sensitivity and specificity of HRFs for detecting LP were calculated using the reference standard defined by clinical long term courses, including information on imaging and biopsy. IOA for presence of individual HRF-CT were "slight" (k=0.119 to k=0.288), for overall suspicion on LP after CT assessment k= 0.308 for HRF-CT, k= 0.289 for RECIST and k= 0.604 after qualitative additional PET assessment. Sensitivity and specificity were 0.22-0.46 and 0.73-0.92 for HRF-CT, 0.30 and 0.94 for RECIST. Qualitative 18F-FDG-PET/CT analysis was highly sensitive (1.0; specificity 0.79), confirmed by interview independent analysis (sensitivity 1.0; specificity 0,85). Semi-quantitative evaluation using SUVmax revealed no further diagnostic benefit (sensitivity 1.0; specificity 0.67). Sensitivity / specificity of CT-assessment versus qualitative PET-assessment for detection of LP were 0.43 / 0,86 and 1,0 / 0,85, respectively. While we could neither confirm RECIST nor defined HRF-CT as reliable predictors of LP, qualitative 18F-FDG-PET/CT assessment seems to offer more diagnostically accurate information about local progression after SBRT, not being improved by quantitative 18F-FDG uptake analysis.

The impact of 18-FDG-PET/CT based target volume delineation on outcome in radio-chemotherapy for locally advanced (LA) non-small cell lung cancer (NSCLC) was evaluated in an international prospective randomized multicenter trial (PET-Plan). A phase II non-inferiority study was performed with LA NSCLC scheduled for combined radio-chemotherapy in 23 trial sites. In 205 of 311 screened patients, target volumes were randomized between a conventional (adjuvant mediastinum to 50 Gy plus dose escalation volume of tumor, atelectasis, FDG-positive and CT-positive nodal stations; arm A) and an experimental (escalation volume FDG-positive tumor and nodal stations only; arm B) approach. In every case, respecting normal tissue constraints (pre-defined in analogy to RTOG 0617), isotoxic dose escalation was performed to achieve the individually highest achievable doses between 60 and 74 Gy/2 Gy. Stringent prospective and retrospective imaging and RT-QA was done during recruitment and follow-up. Simultaneous chemotherapy was given, mainly using platinum and vinorelbine. Primary endpoint was loco-regional progression, main secondary endpoints were infield and outfield progression-free survival, overall survival, and toxicity. After a minimum/mean follow up of 6/22 months, we here report the first results. In the well balanced patient group of 205 patients, 172 were treated as per protocol, being mainly in UICC-stage IIIa (36%) and IIIb (56%) with GTVs of in mean 105 ml. Dose escalation reached in mean 65.3 Gy (A) and 67.3 Gy (B; p=0.007). Loco-regional progression (LRP) was more frequent in arm A (conventional target volume) with a cumulative incidence of 0.29 / 0.39 vs. 0.14 / 0.20 (arm B) after 12 / 24 months (p=0.078). In stratified Cox-models, independent prognostic factors for LRP were study center (p=0.046) and tumor volume (GTV) (p=0.022) while study arm did not reach statistical significance. IMRT (50%) technique did not lead to significantly different results as compared to 3-D-CRT (50%). The 2-year overall survival was 57% (A) vs. 54% (B; n.s.). Neither for local control nor for survival, a positive or negative influence of radiation therapy dose was observed. There was no significant difference for in-field (A: 23% vs. B: 11%; n.s.) and out-field- (A: 11% vs. B: 8%; n.s.) regional recurrences between the study arms. Acute and late toxicity (CTC/ RTOG-EORTC) was mild with no clinically significant difference between the treatment arms. However, SUEs appeared more frequent in arm B. FDG-PET based radiation therapy planning is recommended for isotoxically dose escalated radio-chemotherapy in locally advanced NSCLC. It enabled higher dose escalation and a clear trend to improved local control as compared to conventional planning. The favorable survival results well compare to other recent trials. In contrast to RTOG 0617, no adverse effect of higher treatment doses were observed.

Previous studies using hypoxia PET have shown significant reduction of tumor hypoxia (reoxygenation) during primary radiochemotherapy (RCT) of HNSCC and a significant correlation between reoxygenation on hypoxia PET and local control. Assessment of tumor hypoxia using MRI would offer independence from hypoxia PET tracer availability. The apparent MRI transverse relaxation time T2* has been proposed as an imaging biomarker and as a potential surrogate for hypoxia PET. The aim of this study was to assess the effect of primary RCT on T2* at an early (week 2) and late (week 5) time point during RCT and to analyse the relation between T2* and established hypoxia PET tracer 18F-misonidazole PET/CT (FMISO PET) and standard 18F-FDG PET/CT (FDG PET). In 10 T2-4N+ HNSCC patients, FDG PET was obtained at baseline and repeat FMISO PET and 3 Tesla MRI T2* in weeks 0, 2 and 5. MRI gross tumor volumes for tumor and lymph nodes (GTV-T, GTV-LN) were contoured and FMISO PET derived hypoxic tumor/lymph node subvolumes (HSV-T, HSV-LN) and complementary non-hypoxic subvolumes (nonHSV-T, nonHSV-LN) were generated using a threshold level of 1.4 times the mean SUV FMISO within muscle. Volumes were contoured for all time points (week 0, 2 and 5) individually and mean values for T2* and SUVmean FDG PET were obtained. Within GTVs (T, LN), r2 (FMISO to T2*) was calculated for [FMISO SUVmax GTV/SUVmean muscle] to [T2* mean GTV] and r2 (FMISO to FDG) was calculated for [FMISO SUVmax GTV/SUVmean muscle] to [FDG SUVmax GTV/SUVmean muscle]. From week 0 to 5 GTV-T and GTV-LN decreased by -56% and -63%, respectively and HSV-T and HSV-LN nearly completely resolved (n = 10). Mean T2* signal showed no significant change for GTV-T or GTV-LN. Within HSV-T mean T2* values were smaller compared to nonHSV-T: 15.0+/-4.6 vs. 18.3+/-2.9 (p = 0.051), whereas FDG SUVmean was significantly higher within hypoxic as compared to non-hypoxic regions: HSV-T 12.1+/-5.5 vs. nonHSV-T 6.1+/-2.6 and HSV-LN 10.2+/-3.9 vs. nonHSV-LN 4.7+/-1.9 (week 0, p≤0.026 and p≤0.011). Correlation between FMISO PET and FDG PET was higher than between FMSIO PET and T2*: r2 for GTV-T (FMISO/FDG)=0.81, r2 for GTV-T (FMISO/T2*)=0.32. Marked reduction of tumor hypoxia between week 0, 2 and 5 found on FMISO PET was not accompanied by a significant T2*change within GTVs over time. At baseline, smaller T2* values and significantly larger FDG SUVmean were found within HSV-T as compared to nonHSV-T. These results suggest a relation between tumor oxygenation status and T2* at baseline, however with the correlation coefficient r2 FMISO/T2* being lower than r2 FMISO/FDG. Overall, T2* quantitation was feasible and the findings on T2* imaging warrant further investigations but do not indicate a simple surrogate role for T2* as hypoxia imaging marker due to lack of correlation to established hypoxia marker FMISO PET. Our findings on reduction of FMISO uptake during RCT were in line with previous reports.